← Leaderboards
Vlad C Sandulache
Baylor College Of Medicine
$3,056,791
Attributed
$5,724,755
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.3M · FY2019–25$5M$3.8M$2.5M$1.3M$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,076,849 · 7
VA$0 · 3
By mechanism
U54$6,993,497 · 4
R01$3,278,152 · 1
R21$471,328 · 1
R03$333,872 · 1
I01$0 · 2
IK2$0 · 1
Top collaborators
- Jeffrey Nicholas Myers9 shared
- James A Bankson4 shared
- Stephen Y Lai4 shared
- German Corredor2 shared
- Anant Madabhushi1 shared
Most similar at Baylor College Of Medicine
Same institution · by research overlap
- Sean Hartig$7,561,443
- Ying H Shen$3,916,023
- Scott A Lemaire$7,348,898
- Jessica Beserra Felix$131,190
- William Thomas Shearer$34,592,326
Others in their field
Other Emerging Leaders on “Tumor”
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Lynn Briscoe · Leidos Biomedical Research, Inc.$120,794,323
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$105,180,681
- Leonard Freedmand · Leidos Biomedical Research, Inc.$78,762,245
- Connie Suders · Leidos Biomedical Research, Inc.$67,882,919
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
Research focus
TumorDesignResponseResistanceCisplatinLinkNeoplastic CellMalignant NeoplasmsChemotherapyMetabolicTumor-Immune System InteractionsPre-Clinical ModelTreatment ResponseRegimenSolid NeoplasmImmune Checkpoint InhibitorCarbonStandard Of CareClinical TrialsImageHuman PapillomavirusHead And Neck Squamous Cell CarcinomaGenomicsResistance Development
Grant awards (28)
Leveraging Hyperpolarized MRI for Precision Oncology Approaches in Head and Neck Cancer$1,945,952
R01 · FY2025 · CA
The Houston Center for Acquired Resistance Research (H-CARR)$1,172,214
U54 · FY2025 · CA
Metabolic adaptation enables cisplatin resistance and inhibits tumor immunity$195,369
U54 · FY2025 · CA · contact PI
Activation of immunosupressive oxidative stress response pathways by tobacco exposure in head and neck cancer$0
I01 · FY2025 · VA · contact PI
The Houston Center for Acquired Resistance Research (H-CARR)$1,112,099
U54 · FY2024 · CA
Admin-Core-001$238,959
U54 · FY2024 · CA
The Houston Center for Acquired Resistance Research (H-CARR)$238,959
U54 · FY2024 · CA
Metabolic adaptation enables cisplatin resistance and inhibits tumor immunity$228,275
U54 · FY2024 · CA · contact PI
Determining the impact of ancestry on oropharyngeal cancer biology and treatment response.$208,164
R21 · FY2024 · DE · contact PI
Leveraging Hyperpolarized MRI for Precision Oncology Approaches in Head and Neck Cancer$1
R01 · FY2024 · CA
Activation of immunosupressive oxidative stress response pathways by tobacco exposure in head and neck cancer$0
I01 · FY2024 · VA · contact PI
An imaging AI-driven predictive chemoradiation response tool for Veterans with oropharyngeal cancer$0
I01 · FY2024 · VA · contact PI
The Houston Center for Acquired Resistance Research (H-CARR)$1,174,728
U54 · FY2023 · CA
Leveraging Hyperpolarized MRI for Precision Oncology Approaches in Head and Neck Cancer$657,066
R01 · FY2023 · CA
Determining the impact of ancestry on oropharyngeal cancer biology and treatment response.$263,164
R21 · FY2023 · DE · contact PI
Metabolic adaptation enables cisplatin resistance and inhibits tumor immunity$255,987
U54 · FY2023 · CA · contact PI
Admin-Core-001$254,772
U54 · FY2023 · CA
The Houston Center for Acquired Resistance Research (H-CARR)$254,772
U54 · FY2023 · CA
The Houston Center for Acquired Resistance Research (H-CARR)$162,000
U54 · FY2023 · CA
Metabolic adaptation enables cisplatin resistance and inhibits tumor immunity$162,000
U54 · FY2023 · CA · contact PI
The Houston Center for Acquired Resistance Research (H-CARR)$1,237,322
U54 · FY2022 · CA
Leveraging Hyperpolarized MRI for Precision Oncology Approaches in Head and Neck Cancer$675,133
R01 · FY2022 · CA
Metabolic adaptation enables cisplatin resistance and inhibits tumor immunity$306,041
U54 · FY2022 · CA · contact PI
Improving Treatment Algorithms for Veterans with Oropharyngeal Cancer$0
IK2 · FY2022 · VA · contact PI
Improving Treatment Algorithms for Veterans with Oropharyngeal Cancer$0
IK2 · FY2021 · VA · contact PI
Overcoming cisplatin resistance by targeting fatty acid metabolism$166,936
R03 · FY2020 · DE · contact PI
Improving Treatment Algorithms for Veterans with Oropharyngeal Cancer$0
IK2 · FY2020 · VA · contact PI
Overcoming cisplatin resistance by targeting fatty acid metabolism$166,936
R03 · FY2019 · DE · contact PI